Hood River Capital Management LLC - AGIOS PHARMACEUTICALS INC ownership

AGIOS PHARMACEUTICALS INC's ticker is AGIO and the CUSIP is 00847X104. A total of 192 filers reported holding AGIOS PHARMACEUTICALS INC in Q2 2019. The put-call ratio across all filers is 1.15 and the average weighting 0.1%.

Quarter-by-quarter ownership
Hood River Capital Management LLC ownership history of AGIOS PHARMACEUTICALS INC
ValueSharesWeighting
Q2 2021$10,786,000
+5.6%
195,721
-1.1%
0.32%
-2.4%
Q1 2021$10,216,000
+8.4%
197,823
-9.0%
0.33%
+5.4%
Q4 2020$9,421,000
+25.8%
217,435
+1.7%
0.31%
-4.0%
Q3 2020$7,487,000
-40.4%
213,900
-8.9%
0.32%
-42.3%
Q2 2020$12,560,000
+50.8%
234,850
+0.0%
0.56%
+18.3%
Q1 2020$8,329,000
-26.5%
234,738
-1.1%
0.48%
-2.9%
Q4 2019$11,336,000
+59.0%
237,404
+7.9%
0.49%
+34.6%
Q3 2019$7,130,000
-34.5%
220,063
+0.9%
0.36%
-28.8%
Q2 2019$10,880,000
-23.3%
218,130
+3.7%
0.51%
-28.4%
Q1 2019$14,188,000
+40.5%
210,376
-4.0%
0.71%
+20.0%
Q4 2018$10,101,000
-8.8%
219,067
+52.6%
0.60%
+21.4%
Q3 2018$11,073,000
-5.2%
143,579
+3.5%
0.49%
-18.3%
Q2 2018$11,685,000
+7.2%
138,728
+4.1%
0.60%
-2.0%
Q1 2018$10,903,000
+46.0%
133,322
+2.1%
0.61%
+41.7%
Q4 2017$7,467,000
-7.8%
130,617
+7.6%
0.43%
-16.1%
Q3 2017$8,103,000
+32.5%
121,390
+2.1%
0.52%
+22.0%
Q2 2017$6,115,000
-9.9%
118,844
+2.3%
0.42%
-17.1%
Q1 2017$6,787,000
+44.8%
116,218
+3.5%
0.51%
+24.8%
Q4 2016$4,686,000112,2890.41%
Other shareholders
AGIOS PHARMACEUTICALS INC shareholders Q2 2019
NameSharesValueWeighting ↓
Flagship Ventures 2007 General Partner LLC 1,930,369$118,428,00083.56%
Third Rock Ventures, LLC 3,070,090$188,350,00021.97%
Opaleye Management Inc. 113,500$6,963,225,0005.43%
BB BIOTECH AG 1,890,521$115,983,0004.72%
Eventide Asset Management 431,600$26,479,0003.70%
Atika Capital Management LLC 54,000$3,313,0002.55%
Cormorant Asset Management, LP 100,000$6,135,0001.26%
BRIDGER MANAGEMENT, LLC 220,099$13,503,0000.92%
Ghost Tree Capital, LLC 20,000$1,227,0000.67%
HAMILTON LANE ADVISORS LLC 27,544$1,690,0000.55%
View complete list of AGIOS PHARMACEUTICALS INC shareholders